(Total Views: 474)
Posted On: 09/30/2020 10:29:20 AM
Post# of 149204
Peacekat,
I completely agree. It is a challenge with a new disease and shifting expectations to guess correctly when designing trials. Though only P2, CD10 was successful.
Unfortunately m/m not a clinical indication about which fda seems to care any longer.
Severe/critical and long haulers/persistent dysfunction seem to be current focus.
Hopefully Cytodyn is ahead of us and following up with CD10 and EIND patients as suggested by Rubraquercus.
I completely agree. It is a challenge with a new disease and shifting expectations to guess correctly when designing trials. Though only P2, CD10 was successful.
Unfortunately m/m not a clinical indication about which fda seems to care any longer.
Severe/critical and long haulers/persistent dysfunction seem to be current focus.
Hopefully Cytodyn is ahead of us and following up with CD10 and EIND patients as suggested by Rubraquercus.
(1)
(0)Scroll down for more posts ▼
